MedTech Europe's Brexit Challenge: Don't Forget The Kid In The EU Divorce
Executive Summary
The UK continues to press for favorable trading and regulatory conditions with the EU in its Brexit planning. But EU negotiators seem likely to play it by the book, with no favors shown. The medtech industry watched as the EU withdrawal agreement was approved by the EU27 at the March 2018 Euro Summit. Some weeks prior to that, MedTech Europe chief executive Serge Bernasconi told In Vivo of his fears for EU medtech if the industry was too slow in preparing for UK withdrawal.
You may also be interested in...
UK Medtechs Get A Touch More Certainty With Brexit Transition Agreement
With the UK scheduled to leave the EU one year, the UK medtech and lifesciences industries were becoming increasingly concerned about the government's lack ofplanning and the risk of being left high and dry in the post-Brexit environment. But the UK has bought more time now that the EU agreed to a withdrawal transition phase until the end of 2020. There are potentially meaningful positives in the agreement for medtechs on either side of the English Channel.
A Message For Medtechs: Adapt For the Future While You Can
With the World Health Organization pressing for an inquiry into the coronavirus pandemic, it is clear that lessons must be learned for how future global public health emergencies must be handled. Medical technology has played a key role in halting the speed of the pandemic, but why has it taken an episode like COVID-19 for medtech’s true value to be recognized? ZS principal Brian Chapman says things must never go back to where they were.
UK’s COVID-19 Track-And-Trace Confusion Persists
Surveillance and track-and-trace have emerged as the new focus of the UK’s COVID-19 control strategy, but a workable plan is yet to crystalize.
Need a specific report? 1000+ reports available
Buy Reports